A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO® for 12 Months

Running, not enrolling · Phase 4

Conditions studied: Hypogonadism

In brief

TOL-CLAR-20024 is a Phase 4, multi-center, open-label safety study evaluating the potential effect of JATENZO on adrenal function in hypogonadal men treated with JATENZO for 12 months.

Key facts

Study ID: NCT06385509
Run by: Tolmar Inc.
People needed: 110
Starts: 2024-05-10
Expected to finish: 2026-03-01
Last updated by the study team: 2025-09-04

Who can join

Age: 18 and older, up to 65. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

Subject must be a man 18 to 65 years of age, inclusive, with a previous clinical diagnosis of hypogonadism (signs/symptoms consistent with hypogonadism and a low T level as defined by established criteria at the time of diagnosis); subjects must also have at least 1 T level < 300 ng/dL at either Screen 1 or Screen 2.
Subject must be naïve to androgen replacement therapy or washed out of prior androgen replacement therapies (wash out durations specified in exclusion criterion); that is, be willing to cease current T treatment, or currently not be taking T treatment.
Subject agrees as part of signed informed consent to remain off all forms of T, except for dispensed study drug, throughout the entire study.
Subject must have adequate venous access in the left or right arm to allow collection of blood samples.
Subject must be able and willing to provide written informed consent and comply with the trial protocol and procedures.

You may not qualify if…

Subject will be excluded if 1 or more of the main exclusion is applicable:
Subject with a history of panhypopituitarism or multiple endocrine deficiencies (whether or not on stable doses of thyroid hormone and adrenal replacement hormones).
Subject with a current or prior history of AI.
Subject is currently receiving corticosteroids.
On the CST at Screen 3, the maximum serum total cortisol at both the 30- and 60-minute timepoint is ≤ 14 mcg/dL or has a baseline CBG outside the reference range.
Subject with a history of a short course (2 weeks or less) of any glucocorticoids within the past 3 months or anabolic steroids other than testosterone within the past 6 months.
Subject with a history of a protracted course of any glucocorticoid therapy (e.g., inhaled nasal steroids, inhaled oral steroids, topical steroids, injectable steroids such as joint injections) or anabolic steroids other than T. Enrolled subjects who take glucocorticoids while on study drug may be discontinued from the study at the discretion of the investigator in consultation with the sponsor.
Subject with a history of anabolic steroid abuse.
Subject with a diagnosis of hypogonadism who has received any topical (e.g., gel or patch), intranasal, or buccal T therapy within the previous 2 weeks, intramuscular T injection of short-acting duration (e.g., T enanthate, T cypionate) within the previous 4 weeks, intramuscular T injection of long-acting duration (e.g., AVEED®) within the previous 20 weeks, T implantable pellets (Testopel®) product within the previous 6 months or any prior use of an oral testosterone product.
Subject has received any drug as part of another research study within 30 days of initial dose administration in this study.
Subject has significant intercurrent disease (e.g., liver, kidney, inflammatory bowel disease, uncontrolled or poorly controlled heart disease, including hypertension, thromboembolism, congestive heart failure, or coronary heart disease, psychiatric illness, including severe depression), which in the opinion of the Investigator, would affect study participation or interpretation of study assessments.
Subject has untreated, severe obstructive sleep apnea.
Subject has clinically significant abnormal laboratory values, including serum transaminases > 2 × upper limits of normal (ULN), serum bilirubin > 1.5 × ULN (except subjects with Gilbert syndrome) and serum creatinine > 1.5 × ULN.
Subject has a HCT value of < 35% or > 50%.
Subject has a history of polycythemia, either idiopathic or associated with TRT treatment.
Subject is diabetic with a glycosylated hemoglobin > 8.5%.
Subject has a body mass index (BMI) ≥ 38 kg/m2.
Subject has had a recent (within 2 years) history of stroke, transient ischemic attack, or acute coronary event.
Subject has a mean (triplicate assessments) systolic blood pressure (sBP) > 140 mm Hg and/or diastolic blood pressure (dBP) > 90 mm Hg at screening (if prescribed antihypertensives, subject should be taking medications on the day of the screening visit with a sip of water).
Subject has had recent (within 2 years) history of angina or stent (coronary or carotid) placement.
Subject does not meet the requirements for concomitant medication as outlined below:
If hypertensive, on a stable dose of antihypertensive medication for < 3 months
If diabetic, on a stable dose of oral medication for < 2 months
If on anticonvulsant therapy, on a stable dose for < 3 months
If on lipid lowering medications, on a stable dose for < 3 months. Subject is expected to remain on a stable dose of lipid-lowering medication(s) throughout the study.

Where it is running

Alliance for Multispecialty Research — Tempe, Arizona, United States
Clinical Trials Research — Lincoln, California, United States
Long Beach Research Institute, LLC — Long Beach, California, United States
Integrated Clinical Research — Tarzana, California, United States
Hillcrest Medical Research, LLC — DeLand, Florida, United States
Global Health Clinical Trial Crop — Miami, Florida, United States
Reserka LLC — Miami, Florida, United States
Renstar Medical Research — Ocala, Florida, United States
Clinical Research Center of Florida — Pompano Beach, Florida, United States
Velocity Clinical Research — Savannah, Georgia, United States
Centennial Medical Group — Columbia, Maryland, United States
Velocity Clinical Research — Omaha, Nebraska, United States
AccuMed Research Associates — Garden City, New York, United States
Rochester Clinical Research, LLC — Rochester, New York, United States
Velocity Clinical Research, Inc. — Durham, North Carolina, United States
Catawba Valley Medical Group, Inc. — Hickory, North Carolina, United States
Raleigh Medical Group — Raleigh, North Carolina, United States
Piedmont Healthcare, PA — Statesville, North Carolina, United States
Wilmington Health, PLLC — Wilmington, North Carolina, United States
Velocity Clinical Research — Austin, Texas, United States
Epic Medical Research LLC — DeSoto, Texas, United States
VAST Clinical Research LLC — Garland, Texas, United States
SMS Clinical Research LLC — Mesquite, Texas, United States
Alpine Research Organization, Inc. — Clinton, Utah, United States
Highland Clinical Research — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.